Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Multidimensional analyses have demonstrated the presence of a unique tumor
microenvironment (TME) in liver cancer. Tumor‐associated macrophages (TAMs) are …

Macrophages are important immune cells in innate immunity, and have remarkable
heterogeneity and polarization. Under pathological conditions, in addition to the resident …

Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Autophagy is a core molecular pathway for the preservation of cellular and organismal
homeostasis. Pharmacological and genetic interventions impairing autophagy responses …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Steady progress over four decades toward understanding the pathogenesis and clinical
consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet …

Successful development of treatments for non-alcoholic fatty liver disease and its
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …